April 13, 2021

TMA Precision Health partners with Geneyx

TMA Spokesperson

Originally Posted by:Press release

“Their cutting-edge platform and global experience allow us to serve patients from an increased set of geographies. Together we are able to provide a fully integrated world-class genomic analysis to our clients, which increases the
speed and power of our ability to support personalized precision healthcare for patients and improve their
quality of life.” 

Israel – Geneyx, a world-leading and globally distributed genetics diagnostic platform has partnered with TMA Precision Health to expand distribution in Latin America and advance precision healthcare options for
its existing users.

BOSTON, MA – Geneyx, Inc an Israel-based developer of genomic analysis and interpretation software, will
integrate services with TMA’s artificial intelligence-based platform to expand their distribution into Latin
America and aid in the identification of personalized interventions and delivery of precision healthcare for
rare and complex disease patients. The Geneyx system provides artificial intelligence-based processing.
“I am extremely proud to be working with Geneyx,” said Joshua Resnikoff, TMA CEO, “Their cutting-edge platform and global experience allow us to serve patients from an increased set of geographies. Together we are able to provide a fully integrated world-class genomic analysis to our clients, which increases the
speed and power of our ability to support personalized precision healthcare for patients and improve their
quality of life.” 

Joshua Resnikoff
Chief Executive Officer

Geneyx and TMA have partnered together to distribute the Geneyx platform into TMA’s growing clinical
partner network across Latin America, to better serve this rapidly emerging diagnostic market.
“We are very excited to be collaborating with TMA. This partnership will enable Geneyx to widen our
distribution and together with TMA’s CDA and RPM platforms further advance our commitment in
delivering comprehensive clinical decision support to diverse global communities”
, said Dave Bullis, CBO
of Geneyx.

Dave Bullis
Chief Business Officer
Geneyx Inc. (USA)

The addition of Geneyx’s more than 80,000 cases to TMA’s database of globally rare and complex disease
patients will help further enable the identification of genetic targets with the goal of powering the next
generation of therapeutic development for patients across the rare and complex disease space.

About Geneyx
At Geneyx, we aim to improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around prediction, diagnosis, prognosis, and treatment for clinical and
pharmaceutical organizations. Our AI-based analysis platform is the best choice for clinical, translational, and early
drug discovery efforts looking to scale their genomic interpretation capabilities and leverage the power of precision
medicine.

About TMA
TMA Precision Health (TMAccelerator Company, LLC) is on a mission to improve the lives of rare and complex disease
patients around the globe. TMA’s proprietary “patient first” AI-powered platform delivers personalized precision
healthcare to the patient through their local physician. Our approach creates value and aligns stakeholders at every
level: precision care underpins better outcomes for the patient, improves efficiencies at the clinic, produces significant
savings for the payer, and creates target opportunities for biopharma. Founded by doctors affected by rare diseases,
we have an intimate understanding of the needs of rare and complex disease patients and are riveted on making a
difference in their immediate and long-term quality of life. Our work is backed by global leaders from across the cutting edge of personalized and digital health, biopharma, and academic research. For more information, please visit
tmaprecisionhealth.com


Additional Articles

News

April 13, 2021

TMA Precision Health partners with Geneyx

TMA Spokesperson

Israel - Geneyx, a world-leading and globally distributed genetics diagnostic platform has partnered with TMA Precision Health to expand distribution in Latin America and advance precision healthcare options for its existing users. BOSTON, MA – Geneyx, Inc an Israel-based developer of genomic analysis and interpretation software, will integrate services with TMA’s artificial intelligence-based platform to expand their distribution into Latin America and aid in the identification of personalized interventions and delivery of precision healthcare for rare and complex disease patients. The Geneyx system provides artificial intelligence-based processing,

October 10, 2020

Geneyx Genomex Acquires NGS Sequencing Analysis Firm Toldot Genetics

staff reporter

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

April 8, 2020

Israeli Consortium Launches Patient Sequencing Study to Uncover COVID-19 Genetic Risk Factors

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

Previous
Next

April 13, 2021

TMA Precision Health partners with Geneyx

TMA Spokesperson

Israel - Geneyx, a world-leading and globally distributed genetics diagnostic platform has partnered with TMA Precision Health to expand distribution in Latin America and advance precision healthcare options for its existing users. BOSTON, MA – Geneyx, Inc an Israel-based developer of genomic analysis and interpretation software, will integrate services with TMA’s artificial intelligence-based platform to expand their distribution into Latin America and aid in the identification of personalized interventions and delivery of precision healthcare for rare and complex disease patients. The Geneyx system provides artificial intelligence-based processing,

October 10, 2020

Geneyx Genomex Acquires NGS Sequencing Analysis Firm Toldot Genetics

staff reporter

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

April 8, 2020

Israeli Consortium Launches Patient Sequencing Study to Uncover COVID-19 Genetic Risk Factors

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation